Roadzen to Participate in Fireside Chat at the Maxim Group TMT Conference on June 4, 2024
May 24, 2024 08:30 ET
|
Roadzen Inc.
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- Roadzen Inc. (Nasdaq: RDZN) ("Roadzen" or the "Company”), a global leader in AI at the convergence of insurance and mobility, today announced that it will...
Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 22, 2024 13:30 ET
|
Virios Therapeutics
ATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel...
HEALWELL AI Closes Upsized $20 Million Bought Deal Offering
May 22, 2024 10:09 ET
|
HEALWELL AI Inc.
HEALWELL AI CLOSES UPSIZED $20 MILLION BOUGHT DEAL OFFERING
Edible Garden Announces Pricing of $6.0 Million Public Offering
May 22, 2024 09:15 ET
|
Edible Garden AG Incorporated
BELVIDERE, NJ, May 22, 2024 (GLOBE NEWSWIRE) -- Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally...
ClimateRock Appoints Dariusz Sliwinski to the Board of Directors
May 21, 2024 16:15 ET
|
ClimateRock
LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- ClimateRock (NASDAQ: CLRC) (“ClimateRock” or the “Company”), a special purpose acquisition company formed for the purpose of entering into a merger, share...
Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million
May 20, 2024 08:01 ET
|
Inhibikase Therapeutics
BOSTON and ATLANTA, May 20, 2024 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing protein kinase...
Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 19, 2024 20:53 ET
|
Virios Therapeutics
ATLANTA, May 19, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel...
Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study
May 17, 2024 16:10 ET
|
Virios Therapeutics
ATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company” or “Virios Therapeutics”), a development-stage biotechnology company focused on advancing novel...
ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update
May 15, 2024 16:05 ET
|
ReShape Lifesciences Inc
Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 ...
Draganfly Announces First Quarter Results of 2024
May 14, 2024 17:20 ET
|
Draganfly Inc
Vancouver, BC., May 14, 2024 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems...